Compliance · Pharma Marketing · 2026

UCPMP 2024 Pharma Advertising — The 8 Violations We See Most Often in Indian Pharma Marketing

Q: What is UCPMP 2024 and why does it matter for pharma advertising?

The Uniform Code for Pharmaceuticals Marketing Practices (UCPMP) 2024 is India's government code governing how pharma companies and their marketing partners promote products to healthcare professionals and the public. It matters because it directly shapes what claims content can make, who it can target, and what it can offer HCPs — violations create real regulatory and reputational exposure.

Q: Is UCPMP 2024 legally binding on pharma companies in India?

Yes, UCPMP 2024 was notified as a mandatory code by the Department of Pharmaceuticals, replacing the earlier voluntary version. Non-compliance can trigger regulatory action against the company, and by extension exposes the marketing agencies producing the underlying content and campaigns.

Q: What is the most common UCPMP violation in digital pharma advertising?

Unsubstantiated efficacy and comparative claims are the most frequent violation we encounter — content asserting a product is superior, faster, or safer than an unnamed alternative without a documented citation to approved product information or clinical data on file.

Q: Can pharma companies run consumer-facing ads for prescription drugs in India?

Direct-to-consumer advertising of prescription drugs is heavily restricted under Indian law and UCPMP. Consumer-facing pharma content should generally stay at the disease-awareness level rather than naming and promoting a specific prescription brand.

Q: Are doctor testimonials and influencer endorsements allowed under UCPMP 2024?

UCPMP restricts the use of healthcare professionals to endorse or promote specific pharma products, since this blurs the line between independent medical opinion and paid promotion. Testimonial-style content from doctors is one of the categories we flag most often in agency-produced pharma campaigns.

Q: How can a pharma brand audit its existing marketing content for UCPMP compliance?

Start with a structured checklist covering claim substantiation, HCP-versus-consumer content separation, gifts and hospitality references, testimonial use, disease-versus-brand balance, and review sign-off records, then apply it asset by asset. ICG's compliance audit process runs this checklist across a brand's full content library as a starting engagement.

Published 5 September 2026 · 13 min read

By Rohit Gupta · Business & Growth Lead, Ichelon Consulting Group

TL;DR

Unsubstantiated efficacy and comparative claims are the single most common UCPMP violation we find in pharma content audits.
Brand-forward consumer content disguised as disease education is a close second, and often the hardest for internal teams to self-detect.
Doctor testimonials, gift-adjacent event content, and mixed HCP/consumer claim standards round out the recurring pattern.
Every violation on this list has a specific, fixable process gap — not a reason to slow content output, just to route it correctly.
Download our free UCPMP audit checklist at the end to run this same 8-point check against your own content library.

Why we are seeing the same eight violations across brands

Since UCPMP 2024 was notified, we have run compliance audits across pharma marketing content for a range of Indian brands and the agencies producing content on their behalf. What surprised us was not the variety of problems — it was how narrow the pattern actually is. The same eight violation types show up again and again, regardless of therapy area, company size, or whether the content was produced in-house or by an external agency.

That consistency is actually useful news. It means UCPMP compliance in pharma marketing is not a vague, hard-to-pin-down risk — it is a short, specific list of failure modes that a disciplined review process catches reliably once you know what to look for. Most of the violations we see are not the result of anyone deliberately cutting corners; they come from content teams working under brand-recall pressure, using templates and habits that predate the 2024 code, or simply not having a documented checklist to check work against before it publishes.

This piece walks through the eight violations in the order we encounter them most often, with the specific fix for each. If you want to run this check against your own content library directly, the downloadable checklist at the end mirrors this exact structure.

The 8 UCPMP 2024 violations, ranked by how often we see them

1. Unsubstantiated efficacy or comparative claims

The violationContent asserting a product works "faster," "better," or is "more effective" than an unnamed alternative, without a documented citation back to approved product information or clinical data on file. This is by far the most frequent finding in our audits — often buried in a single adjective in an otherwise compliant piece of content.

The fixEvery efficacy or comparative word in a draft — faster, safer, superior, proven, clinically shown — needs a traceable citation attached before it goes into content. If the writer cannot point to the specific line in the approved product information or clinical dossier, the claim gets cut or softened to a general statement, no exceptions.

2. Brand-forward content dressed up as disease education

The violationA piece nominally structured as disease-awareness content — symptoms, causes, when to see a doctor — that in practice spends most of its length steering the reader toward a specific branded product. This one is subtle because the surface structure looks compliant; the violation is in the emphasis and word count allocation, not any single sentence.

The fixApply a simple test to every consumer-facing draft: remove the brand name entirely and check whether the content still reads as genuinely useful, standalone disease education. If it collapses into incoherence without the brand mention, it was never disease-education content — it needs restructuring around the disease itself, with brand mention reduced to a clearly secondary reference.

3. Direct-to-consumer promotion of prescription products

The violationConsumer-facing ads, landing pages, or social content that names and promotes a specific prescription drug to the general public — heavily restricted under Indian law and UCPMP, yet still surprisingly common in digital campaigns that were built by teams more familiar with over-the-counter marketing conventions.

The fixMap every planned consumer-facing asset against a simple rule before production starts: prescription-only products get disease-awareness content at most for a general audience, with brand-level promotion reserved strictly for HCP-gated channels. This needs to be a pre-production gate, not a post-hoc content edit.

4. Doctor testimonials and influencer-style endorsements

The violationContent featuring a named or visually identifiable healthcare professional appearing to personally endorse or recommend a specific pharma product — a format that blurs independent medical opinion with paid promotion, and one we see recur particularly in video and social campaigns where the format feels more natural than it should.

The fixReframe HCP-featuring content around general medical education delivered by the professional in their expert capacity, rather than product-specific recommendation. Where a KOL relationship exists, disclose it clearly and keep the content focused on disease or category education rather than a specific brand endorsement.

5. Gift, hospitality, and event content that reads as an inducement

The violationMarketing content around medical conferences, CME events, or HCP hospitality that, in tone or specificity, functions as promotion of the gifts and hospitality itself rather than genuine medical education — UCPMP places strict limits on gifts and hospitality to HCPs, and content marketing these events needs to stay on the right side of that line.

The fixKeep event-related content focused on the educational agenda and content, not the hospitality elements — venue, meals, gifts. Any reference to hospitality provisions should be factual and minimal, never used as a promotional hook to drive attendance.

6. Mixing HCP-directed and consumer-directed claim standards

The violationPublishing HCP-appropriate clinical detail — specific efficacy data, detailed comparative claims — on a general-access website page or public social account, without the access gating that would make that claim standard appropriate for the audience actually reaching it.

The fixBuild a genuinely gated HCP content structure — professional verification required for access — separate from the public-facing site, rather than relying on audience self-selection or a soft disclaimer to keep the two claim standards apart. ICG's pharma content workflows build this architecture in from the first content sprint.

7. Skipping formal review for short-form and social content

The violationTreating Instagram captions, LinkedIn posts, or short video scripts as lower-stakes than long-form content and publishing them without the same documented compliance review — even though UCPMP applies regardless of format, and short-form content's speed and volume make it the channel where unsubstantiated claims most often slip through undetected.

The fixRoute every asset, regardless of length or channel, through the same documented sign-off step before publish. A one-line social caption takes seconds to check against a checklist — the discipline matters more than the asset's apparent size.

8. No documented, named reviewer or audit trail

The violationCompliance review happening as an informal read-through by whoever is available, with no dated record of who reviewed which asset against which version of the product information — meaning there is no audit trail if a regulatory question arises later, and no way to demonstrate a functioning compliance process rather than an ad hoc one.

The fixName a specific regulatory or medical affairs reviewer, require their dated sign-off on every asset before publish, and log it against the product information version used. This single process change is often the fastest way to move a brand's content programme from exposed to defensible.

How to run this check on your own content library

The fastest way to apply this list is asset by asset, not as a one-time sweep. Pull your last quarter of published pharma marketing content — website pages, social posts, campaign landing pages, and any HCP-facing material — and run each piece against all eight violation categories above. Flag anything that trips even one category for revision, and track the pattern of where flags cluster; in most brands we audit, three or four of the eight account for the large majority of findings.

For an ongoing programme rather than a one-time audit, the sustainable fix is building the checklist into the production workflow itself — a documented gate before publish, not a retrospective cleanup exercise. Teams that catch this at review stage, before an asset ever goes live, spend a fraction of the time that teams spend correcting published content after the fact.

Where content strategy and compliance intersect most directly is in how a brand's pharma marketing programme is structured from the start — campaign planning, content production, and compliance review need to run as one connected workflow rather than compliance being bolted on at the end.

Free download

Get our 8-point UCPMP audit checklist — the exact structure used in this article, formatted for running against your own content library asset by asset.

💬 WhatsApp for the checklist

What ICG does here

We run UCPMP compliance review as a built-in part of every pharma content engagement, not an optional add-on. That starts with an audit of a brand's existing content library against the eight categories above, then continues into a documented review gate for every new asset we produce — website content, campaign creative, and social — under our healthcare content marketing and pharma marketing workflows. Retainers from ₹20,000/month · Custom-scoped per engagement, with the compliance review layer included rather than billed separately.

Get your pharma content library audited against these 8 violations

Book a free 30-minute Benchmarking call and we will review a sample of your current content against the UCPMP 2024 checklist — free, no obligation.

💬 WhatsApp ICG Chat with Co-founder

FAQ

What is UCPMP 2024 and why does it matter for pharma advertising?

India's code governing how pharma companies market to HCPs and the public — it directly shapes what content can claim, who it can target, and what it can offer HCPs.

Is UCPMP 2024 legally binding on pharma companies in India?

Yes — notified as mandatory by the Department of Pharmaceuticals, replacing the earlier voluntary version.

What is the most common UCPMP violation in digital pharma advertising?

Unsubstantiated efficacy and comparative claims — the top finding across our audits.

Can pharma companies run consumer-facing ads for prescription drugs in India?

Direct-to-consumer prescription advertising is heavily restricted; consumer content should stay at disease-awareness level.

Are doctor testimonials and influencer endorsements allowed under UCPMP 2024?

Restricted — content featuring HCPs personally endorsing a specific product is one of our most frequent findings.

How can a pharma brand audit its existing marketing content for UCPMP compliance?

Run a structured checklist across claim substantiation, HCP/consumer separation, gifts references, testimonials, and review sign-off — asset by asset.

Compliance DCGI / UCPMP 2024 Pharma marketing code compliance overlay for ChatGPT Ads copy. DPDP Act 2023 Consent-flow and data-handling rules for conversational lead capture.

Case scenarios Pharma Brand, OTC Cough & Cold Growth-tier UCPMP-clean campaign for an OTC pharma brand. Dermatology Clinic, Single Location Starter-tier conversational bidding for a solo dermatology practice.

Glossary ChatGPT Ads What conversational advertising inside ChatGPT actually means. UCPMP-Clean Copy Pharma ad copy standards under the UCPMP 2024 code. Entity Signal How AI assistants recognise a brand as a real, citable entity.

Exploring ChatGPT Ads for healthcare? Visit the ChatGPT Ads pillar →